Jazz Pharmaceuticals JAZZ Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.44B+9.2% | $4.27B+4.9% | $4.16B+4.1% | $4.09B+4.5% | $4.06B+5.8% | ||
| —— | —— | —— | —— | —— | ||
| $1.65B+6.5% | $1.81B+30.6% | $1.77B+25.5% | $1.57B+12.4% | $1.55B+10.8% | ||
| $4.48B+29.0% | $4.7B+40.1% | $4.65B+39.1% | $4.38B+30.7% | $3.47B+4.4% | ||
| —— | —— | -$494.01M-176% | -$291.31M-152% | $594.52M+14.6% | ||
| $262.36M-19.8% | $248.56M-21.0% | $352.02M-3.7% | $341.9M-3.0% | $327.24M-4.1% | ||
| —— | —— | -$11.17M+56.5% | -$10.85M+58.8% | $3.2M+111% | ||
| —— | —— | -$703.1M-276% | -$511.33M-272% | $362.15M+50.1% | ||
| -$253.49M-110% | -$277.39M-203% | -$335.31M-403% | -$107.42M-8.2% | -$120.9M-30.1% | ||
| —— | —— | -$368.44M-180% | -$404.8M-203% | $482.24M+45.8% | ||
| —— | —— | -$6.16-187% | -$6.82-217% | $7.41+52.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Jazz Pharmaceuticals's revenue?
- Jazz Pharmaceuticals (JAZZ) generated $4.4B in revenue over the trailing twelve months, up 9.2% year over year.
- Is Jazz Pharmaceuticals profitable?
- Jazz Pharmaceuticals is not currently profitable: it reported a net loss of $266.5M over the trailing twelve months, a -8.9% net margin.
- What is Jazz Pharmaceuticals's earnings per share?
- Jazz Pharmaceuticals's diluted EPS over the trailing twelve months is $-4.75.
- Where does Jazz Pharmaceuticals's income statement data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
